Researchers conducted the ACHIEVE-1 trial to assess the effect of orfoglipron on glycemic control among patients with early-stage type 2 diabetes.

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

YourChoice Therapeutics, a biotech company based in California, has reported promising safety data from an early-stage ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

A total of 4 new recommendations are included as part of the American Academy of Dermatology’s atopic dermatitis guideline updates.

Dear: My husband and I are in our 50’s and would like to know what resources you recommend for locating senior discounts, and ...

Icotrokinra is designed to selectively block the IL-23 receptor, which drives inflammation in plaque psoriasis and ...

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

Lyme disease is a complex condition with a long history of misdiagnosis, and Lyme arthritis, a late manifestation of the ...

Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who ...

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...